Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
- Status
- WithdrawnStopped: A study start is currently not foreseeable for organizational reasons. Due to the delays, research has also been focused on new compounds, which has reduced the interest in the potential results of the above-mentioned clinical trial.
Results none - Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Type 2 Diabetes; Cardiovascular Diseases
- Interventions
- Liraglutide Pen Injector [Victoza]; Placebo
- Conditions
- Type 2 Diabetes; Cardiovascular Diseases
- Phase and size
- Phase 3 · ? participants
- Dates
- Start 2020-11
Primary completion 2022-08 - Sponsor
- RWTH Aachen University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months3 month
02Eligibility
Who can take part
Inclusion Criteria: 1. Type 2 diabetes 2. Serum levels of HbA1c ≥ 7,0% 3. Age ≥ 18 years 4. Patients with existing cardiovascular disease: coronary heart disease, cerebrovascular disease, peripheral vascular disease, chronic kidney disease of stage III or chronic heart failure of NYHA II or III) 5. Written informed consent prior to study participation Exclusion Criteria: 1. Type 1 diabetes 2. Treatment with GLP-1 receptor agonists or DPP-4 inhibitors within the last 4 weeks 3. Patients with familiar or personal history of multiple endocrine neoplasia-type 2 or medullary C-cell cancer 4. Renal impairment (eGFR \< 30 mL/min) 5. Occurrence of acute vascular events within 6 weeks before screening and randomization 6. Known or suspected hypersensitivity to Liraglutide 7. Pregnant females as determined by positive (serum or urine) hCG test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol. 8. Lactating females 9. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication. 10. The subject received an investigational drug within 30 days prior to inclusion into this study. 11. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study. 12. The subject is unwilling or unable to follow the procedures outlined in the protocol. 13. The subject is mentally or legally incapacitated.
03Change log
Registry changes
No changes recorded since the trial was added.